The Pharma Data

JANUARY 17, 2021

LONDON–( BUSINESS WIRE )– Ixaka Ltd , an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies (MCTs) and targeted nanoparticle (TNP) therapeutics.

Therapies 40

Therapies Clinical Trials Immune Response Disease 40

The Pharma Data

OCTOBER 27, 2020

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. SAN DIEGO , Oct. Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 9, 2020

10, 2020 06:00 UTC. Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and they are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. PARIS & CAMBRIDGE, Mass.–(

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

PLOS: DNA Science

JANUARY 4, 2024

The end-of-year FDA approval of the first CRISPR-based therapy , for sickle cell disease, came a mere dozen years after Jennifer Doudna and Emmanuelle Charpentier introduced the technology. They shared the Nobel Prize in Chemistry in 2020. CRISPR is one of the better abbreviations in genetics. It restores vision in just days.

FDA Approval 52

FDA Approval DNA Therapies Clinical Trials 52

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020. CHENGDU, China.–(

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JANUARY 21, 2021

Precigen is focused on next-generation gene and cell therapy using precision technology. In January 2020, it raised $69 million in Series D, bringing the then-total up to $150 million. Pharvaris – Based in The Netherlands, Pharvaris is planning a $100 million Nasdaq IPO to raise money for its therapy for hereditary angioedema (HAE).

Immune Response 52

Immune Response Laboratories Trials Therapies 52

The Pharma Data

NOVEMBER 22, 2020

23, 2020 10:10 UTC. Dr Hussam Shaheen, Director of Antibody Discovery and Engineering at Pandion Therapeutics, said: “Our TALON platform leverages natural immune regulatory mechanisms, to re-balance immune responses and ultimately advance discovery into novel treatments for autoimmune and inflammatory diseases.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

The Pharma Data

DECEMBER 13, 2020

14, 2020 /PRNewswire/ — Synlogic, Inc. Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. Nature Communications 11, 2739 (2020)). CAMBRIDGE, Mass. ,

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

DECEMBER 10, 2020

11, 2020 02:48 UTC. The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

OCTOBER 16, 2020

12 to 16, 2020. 16, 2020 — A case of reinfection with severe acute respiratory syndrome coronavirus 2 is described in a study published online Oct. 14, 2020 — Enrollment in a study testing an experimental antibody therapy against COVID-19 has been paused by independent monitors. FRIDAY, Oct. THURSDAY, Oct.

Hospitals 52

Hospitals Immune Response Trials Vaccine 52

The Pharma Data

NOVEMBER 12, 2020

12, 2020 — Lung cancer patients who harbor certain bacteria in the airways may have a poorer prognosis, a new study finds, adding to evidence that the body’s “microbiome” may play a role in cancer patients’ outlook. © 2020 HealthDay. Posted: November 2020. THURSDAY, Nov. All rights reserved.

Immune Response 52

Immune Response Research Doctors Treatment 52

The Pharma Data

JANUARY 17, 2021

The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses. HFrEF was formerly known as systolic heart failure.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Adicet Bio, Inc. Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. T cell therapies by Adicet, and marks the beginning of clinical development of a deep pipeline of “off-the-shelf” ??

FDA 40

FDA Immune Response Engineering Clinical Trials 40

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Apexigen, Inc. , APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. SAN CARLOS, Calif. , About Apexigen.

Treatment 40

Treatment Immune Response Clinical Trials Clinical Development 40

NIH Director's Blog: Drug Development

MAY 21, 2020

Science, 2020 We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. Preprint Posted May 5, 2020. [2] So, what exactly led up to this latest scientific achievement?

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

NOVEMBER 12, 2020

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. Accessed October 2020. Accessed October 2020. Posted: November 2020. NCT identifier: NCT04380688. Available online.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

Broad Institute

OCTOBER 4, 2023

The molecule’s dual mechanism of action — targeting both tumor and immune cells — is unique compared to other cancer immunotherapies including PD-1 drugs, and the researchers think it could explain why the molecule was so effective on its own in animal models and may not even need to be used in combination with other drugs such as anti-PD-1 therapy.

Small Molecule 128

Small Molecule Clinical Trials Engineering Trials 128

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ 2020 Apr 9;72(9):1435–46. Arthritis Rheumatol.

Immune Response 52

Immune Response Trials Treatment Disease 52

The Pharma Data

JANUARY 19, 2021

TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. In January 2020, it raised $69 million in Series D, bringing the then-total up to $150 million.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. . PLYMOUTH MEETING, Pa. , Only 6 related Grade 1 adverse events in 5 subjects were observed, primarily mild injection site reactions (e.g.,

DNA 40

DNA Vaccine Immune Response Clinical Trials 40

The Pharma Data

DECEMBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. In this difficult to treat patient population, at the first assessment time-point of 6 weeks post-therapy initiation, 100% of the patients were free of disease progression. NEW YORK, Dec. Kenilworth, N.J., with a median follow-up of 9.4 Kenilworth, N.J.,

Immune Response 52

Immune Response Clinical Trials Therapies Trials 52

SugarCone Biotech

MAY 28, 2019

Lymphoid Structures Drive Immune Checkpoint Therapy and the Efficacy of Cellular Therapeutics (a reboot from 2020) We’d been hearing the rumors for months. is focused on the response of sarcomas to immunotherapy ( [link] ). These observations suggest that B cells and TLS are important for successful ICB therapy.

Immune Response 52

Immune Response Therapies Production Vaccine 52

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer?BioNTech In December 2020, Pfizer announced that the U.S. The Pfizer?BioNTech

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 06:00 UTC. NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. PARIS & CAMBRIDGE, Mass.–(

Clinical Trials 52

Clinical Trials Immune Response Trials Therapies 52

The Pharma Data

DECEMBER 28, 2020

29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. . HOUSTON , Dec.

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 10:45 UTC. Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. KENILWORTH, N.J.–(

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy.

Clinical Trials 52

Clinical Trials Trials Hospitals Vaccine 52

The Pharma Data

AUGUST 20, 2020

These results informed the selection of the BNT162b2 candidate for the pivotal Phase 2/3 global study in up to 30,000 participants that started in July 2020, which has to date enrolled more than 11,000 participants, including in areas with significant SARS-CoV-2 transmission. billion doses by the end of 2021. billion doses by the end of 2021.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

DECEMBER 27, 2020

28, 2020 13:00 UTC. NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021. CARLSBAD, Calif.–( –( BUSINESS WIRE )– Lineage Cell Therapeutics, Inc.

Therapies 52

Therapies Clinical Trials Production Treatment 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. In the U.S.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

JANUARY 11, 2021

Testing Therapies, Antivirals and Vaccines. Despite some controversy over its effectiveness, it is bolstering the company’s bottom line and Gilead recently updated its 2020 guidance to reflect that. In clinical trials, it could detect COVID-19 with 90%+ accuracy in about two minutes. .

Vaccine 52

Vaccine Clinical Trials Immune Response Trials 52

The Pharma Data

SEPTEMBER 9, 2020

The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval. Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

MARCH 16, 2021

1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. Our latest solution provides laboratories a fast and efficient way to investigate these variants found in infected individuals and the potential impact on existing therapies, vaccines and tests.”. First reported in the UK in December 2020, B.1.1.7

Clinical Trials 52

Clinical Trials Laboratories Virus Vaccine 52

The Pharma Data

NOVEMBER 19, 2020

As of November 15, 2020, according to the U.S. Census Bureau and compared the provisional non-COVID-19 death numbers for 2020. They found a significant increase in excess deaths in 2020 in men between 15 and 59 years of age and for women between 25 and 44. with at least 799 recorded deaths. Source link.

Research 52

Research Nurses Disease Immune Response 52